7:00 AM ET
8-K
Business Update
NovoCure Business Update
NovoCure received a Not Approvable Letter from the FDA regarding its Premarket Approval (PMA) application for Optune Mya for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the degree of clinical benefit rather than safety concerns, and the company plans to meet with the regulator to discuss potential paths forward without additional clinical studies.